Cited 0 times in Scipus Cited Count

Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer

Authors
Shim, SH | Lee, JY | Lee, YY | Park, JY | Lee, YJ | Kim, SI | Han, GH | Yang, EJ | Noh, JJ | Yim, GW | Son, JH  | Kim, NK | Kim, TH | Kong, TW  | Choi, YJ | Cho, A | Lim, H | Jang, EB | Cho, HW | Suh, DH
Citation
Journal of gynecologic oncology, 35(2). : e66-e66, 2024
Journal Title
Journal of gynecologic oncology
ISSN
2005-03802005-0399
Abstract
In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.
Keywords

MeSH

DOI
10.3802/jgo.2024.35.e66
PMID
38330382
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Ajou Authors
공, 태욱  |  손, 주혁
Full Text Link
Files in This Item:
38330382.pdfDownload
Export

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse